Letter: programmed death‐1—a predictor for antiviral treatment in chronic hepatitis B. Authors' reply

Abstract

LINKED CONTENT This article is linked to the Xia et al and Vyas papers. To view these articles, visit https://doi.org/10.1111/apt.15732 and https://doi.org/10.1111/apt.15878

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply

“…

Editors,We would like to express our gratitude to Huang et al for their insightful comments on our study. 1,2 In response to the first query, we agree that fatty liver may be associated with the risk of chronic kidney disease (CKD) development. The number of patients with fatty liver by imaging studies such as ultrasonography was 191 (18.3%), 528 (19.7%), 172 (22.7%) and 1376 (22.3) in the entecavir, tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) and untreated group, respectively.

…”